ClariTest from GenPath:The Right Choice for Non-Invasive Prenatal Testing
ClariTest™ from GenPath harnesses the power of massively parallel sequencing to screen for fetal chromosomal abnormalities.ClariTest is a safe, non-invasive prenatal test (NIPT), performed as early as 10 weeks of gestation from a simple blood draw, exhibiting outstanding sensitivity and specificity for the most common trisomies and specific microdeletion syndromes.
ClariTest Screens for Microdeletion Syndromes
ClariTest can screen for five microdeletions that result in the following syndromes:
22q11.2 deletion syndrome (DiGeorge syndrome)
1p36 deletion syndrome
15q11.2 deletions (Angelman or Prader Willi syndrome)
Cri du chat syndrome (5p-)
Wolf-Hirschhorn syndrome (4p-)

Collectively these microdeletions can affect 1 in 1000 pregnancies and have clinical features that can affect growth, intellectual ability and/or development.